← Back to Clinical Trials
Recruiting NCT03218332

NCT03218332 Post-Concussion Syndrome in Professional Athletes: A Multidisciplinary Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03218332
Status Recruiting
Phase
Sponsor University Health Network, Toronto
Condition Chronic Traumatic Encephalopathy
Study Type OBSERVATIONAL
Enrollment 150 participants
Start Date 2011-07-04
Primary Completion 2030-12-30

Eligibility & Interventions

Sex Male only
Min Age 25 Years
Max Age 85 Years
Study Type OBSERVATIONAL
Interventions
Biomarkers for detecting possible CTE invivo

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 150 participants in total. It began in 2011-07-04 with a primary completion date of 2030-12-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

to examine the relationship between repeated concussions and late decline of brain function. In addition, all participants agreeing to participate in the study will be asked to will their brains to The Krembil Neuroscience Centre Concussion Project at the Toronto Western Hospital with the consent and full knowledge of their families and doctors. However, it is possible to participate in the research without agreeing to a brain donation. The Project Team is specifically attempting a clinical-MRI-brain tissue research analysis to determine the exact mechanism of the damage to brain tissue following repeated concussions. This condition is known as chronic traumatic encephalopathy (CTE), and shows an abnormal protein in the brain called tau-protein.

Eligibility Criteria

Inclusion Criteria: fluent in English, and a history of multiple concussions , low exposures , or no concussions (Control group ). Determination of concussion exposure will be determined as follows: Previous concussion will be based on the player's recall of injury and defined as "an injury resulting from a blow to the head that caused an alteration in mental status and one or more of the following symptoms: headache, nausea, vomiting, dizziness/balance problems, fatigue, trouble sleeping, drowsiness, sensitivity to light or noise, blurred vision, difficulty remembering, and difficulty concentrating. Exclusion Criteria: Neurological disorders prior to concussions (e.g.: seizure disorder); systemic illnesses known to affect the brain (e.g., diabetes and lupus); a history of psychotic disorder; known developmental disorders (e.g., attention deficit disorder, dyslexia); history of migraines; and, active engagement in litigation.

Contact & Investigator

Central Contact

Mozhgan Khodadadi, MA

✉ Mozhgan.Khodadadi@uhn.ca

📞 416-603-5800

Principal Investigator

Maria Carmela Tartaglia, M.D

PRINCIPAL INVESTIGATOR

Toronto Western Hopsital,UHN;Tanz CRND

Frequently Asked Questions

Who can join the NCT03218332 clinical trial?

This trial is open to male participants only, aged 25 Years or older, up to 85 Years, studying Chronic Traumatic Encephalopathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03218332 currently recruiting?

Yes, NCT03218332 is actively recruiting participants. Contact the research team at Mozhgan.Khodadadi@uhn.ca for enrollment information.

Where is the NCT03218332 trial being conducted?

This trial is being conducted at Toronto, Canada.

Who is sponsoring the NCT03218332 clinical trial?

NCT03218332 is sponsored by University Health Network, Toronto. The principal investigator is Maria Carmela Tartaglia, M.D at Toronto Western Hopsital,UHN;Tanz CRND. The trial plans to enroll 150 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology